ASCO 2013- Immunoterapy

1. Genitourinary Cancers Track
Hospital “Hermanos Ameijeiras” 10- 12 de julio del 2013
Immunotherapy's in trials

2. Castration Resistant
Prostate Cancer (CRPC)
Immunotherapy´s in trials
 Sipuleucel T (Provenge)
 Prostvac
 Ipilimumab
 PSMA mAb conjugated with citotoxic drug (PSMA ADC)
 Anti STEAP1 mAb conjugated with citotoxic drug (STEAP1 ADC)
 Aflibercept
 Denosumab

3. Presented By James L. Gulley, MD, PhD, FACP at 2013 ASCO Annual Meeting
Sipuleucel-T FDA Apr 2010 Prolongued Suvival

4. Presented By James L. Gulley, MD, PhD, FACP at 2013 ASCO Annual Meeting
Sipuleucel-T FDA Apr 2010 Prolongued Suvival

5. Presented By James L. Gulley, MD, PhD, FACP at 2013 ASCO Annual Meeting
Sipuleucel-T FDA Apr 2010 Prolongued Suvival
+ Sequencing is an important question
- Impact on immune parameters not
linked to effectiveness, clinical
relevance of the observation as yet
unclear

6. Presented By James L. Gulley, MD, PhD, FACP at 2013 ASCO Annual Meeting
Prostvac- VF

7. Presented By Slovin SF, MD, PhD, FACP at 2013 ASCO Annual Meeting
Anti CTLA-4 Ipilimumab
Phase I/II
Dose escalation & Cohort
expansion  RT

8. Presented By Slovin SF, MD, PhD, FACP at 2013 ASCO Annual Meeting
Anti CTLA-4 Ipilimumab

9. Presented By James L. Gulley, MD, PhD, FACP at 2013 ASCO Annual Meeting
Ipilimumab combined with Prostvac- VF

10. PSMA mAb conjugated with citotoxic drug (PSMA ADC)
Presented By Petrylak D. at 2013 ASCO Annual Meeting
Phase II trial in taxane resistant mCRPC is
ongoing
Monometil Auristatin E

11. Anti STEAP1 mAb conjugated with citotoxic drug
Presented By Danila DC. at 2013 ASCO Annual Meeting
Monometil Auristatin E

12. Presented By Ian Tannock, MD, PhD, FRCPC, DSc at 2013 ASCO Annual Meeting
Aflibercept
1 224 patients by ITT

13. Presented By Karim Fizazi, MD, PhD at 2013 ASCO Annual Meeting
Denosumab-T FDA Apr 2010 Skeletal Related Events
Non demonstrated role on survival

14. Renal Cell Carcinoma
(RCC)
Immunotherapy´s in trials
 Nivolumab
 Engineered PD-L1 mAb (MPDL3280A )
 Girentuximab: a mAb targeting CAIX (cG250)
 IMA 901: Mixture of synthetic tumor associated peptides
 AGS-003: Autologous dendritic cells & electroporated RNA

15. Presented By Drake CG. at 2013 ASCO Annual Meeting
Nivolumab
A controlled randomized Phase III trial is
ongoing

16. Presented By Daniel C. Cho, MD at 2013 ASCO Annual Meeting
Engineered PD-L1 mAb (MPDL3280A )

17. Presented By Arie S. Belldegrun, M.D. at 2013 ASCO Annual Meeting
Girentuximab: a mAb targeting CAIX (cG250)

18. Presented By Ronald M. Bukowski, MD at 2013 ASCO Annual Meeting
Cancer vaccines in mRCC
 Immune dysregulation in RCC is recognized (Tregs & Myeloid derived suppressor cells)
 No convincing evidence of associated clinical benefit in prospective previous studies with a variety
of autologous and allogenic vaccines
 Novel vaccines in phase III trials:
-IMA 901: Mixture of synthetic tumor associated peptides
-AGS-003: Autologous dendritic cells & electroporated RNA
 The possibility of enhance therapeutics effects by inhibition of immunoregulatory pathways
(checkpoints CTLA4 & PD-1/PD-L1)
Ongoing phase III
trials using cancer
vaccines in mRCC
(IMPRINT & ADAPT)

19. Advanced Urotelial Cancer
Immunotherapy´s in trials
 Ipilimumab

20. Presented By Andrea Borghese Apolo, MD at 2013 ASCO Annual Meeting
?

21. Presented By Andrea Borghese Apolo, MD at 2013 ASCO Annual Meeting
Ipilimumab

22. Cancer Vaccines:
A methodological framework to enhance the
clinical success of cancer immunotherapy
Genitourinary Cancers Track

24. Presented By Gulley James L. at 2013 ASCO Annual Meeting
What do we know so far

25. ¡Muchas gracias!